Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Opposing Oncolytic Virus companies share prices

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon May 24, 2024 1:07pm

110 Views

Post# 36056190

RE:Opposing Oncolytic Virus companies share prices

CG Oncology -> US$33.01 per share a/o May 24, 2024

Today announced final results from the Phase 2 CORE-001 clinical trial of its intravessically delivereed (liquid treatment that is put directly into the bladder through a catheter) ) oncolytic virus immunotherapy candidate, cretostimogene, in combination with pembrolizumab for the treatment of BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)

https://www.wdrb.com/news/national/cg-oncology-to-present-positive-final-results-from-phase-2-core-001-study-of-cretostimogene/article_dee4db41-837e-5a8b-b177-d614bf0e246f.html

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario